Guidelines on drug use in children with ADHD issued

Updated guidelines on the safe use of methylphenidate in children with attention-deficit hyperactivity disorder (ADHD) have been issued by the MHRA.

MHRA guidelines recommend the use of methylphenidate for ADHD treatment (Photograph: SPL)
MHRA guidelines recommend the use of methylphenidate for ADHD treatment (Photograph: SPL)

The guidelines state that methylphenidate is safe to use in children over the age of six, but that healthcare professionals should rigorously monitor patients for cardiovascular and psychiatric problems before and during treatment.

This monitoring should include assessment of height and weight, as well as BP, pulse and symptoms suggestive of heart failure, which should prompt specialist cardiac evaluation. Patients should also be watched for any changes in appetite and for onset or worsening of psychiatric symptoms, the MHRA has said.

Treatment should be interrupted annually to determine whether continuation is necessary, the guidelines say.

The new advice follows a review of the drug's safety by the European Medicines Agency last year.

The MHRA has also announced that patient information leaflets for methylphenidate products are being updated. The new leaflets will include a tear-off section for children and adolescents taking the medication, which has been written in an engaging style designed to appeal to young people with ADHD.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus